Axiom Investors LLC DE Trims Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Axiom Investors LLC DE cut its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,101 shares of the biopharmaceutical company's stock after selling 2,599 shares during the quarter. Axiom Investors LLC DE owned approximately 0.06% of Intra-Cellular Therapies worth $5,020,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. True Wealth Design LLC bought a new position in Intra-Cellular Therapies in the 3rd quarter worth about $32,000. GAMMA Investing LLC grew its holdings in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies in the 3rd quarter valued at approximately $97,000. Finally, Quarry LP boosted its stake in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 1,300 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of "Hold" and a consensus price target of $106.23.

Remove Ads

Intra-Cellular Therapies Stock Performance

ITCI remained flat at $131.87 on Friday. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98. The business's 50 day moving average price is $129.62 and its 200 day moving average price is $101.61. The company has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.